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ABSTRACT
Background: Common Variable Immunodeﬁciency (CVID) is a pri-
mary immunodeﬁciency characterized by an immunologic deﬁciency
in immunoglobulin production. Regulatory T cells (Tregs) play a key
role in preventing the development allergic disorders. p-STAT5 is a
known factor for the function and survival of Tregs. This study aimed
to investigate the number of Tregs and their p-STAT5 expression in
allergic and non-allergic CVID patients.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated
from 10 healthy volunteers, 10 allergic patients, and 16 CVID patients
(allergic and non-allergic) using Ficoll density centrifugation. The
percentage of Tregs in PBMCs was analyzed by ﬂow cytometry.
Tregs were also isolated from participants using an immunomagnetic
separation method and p-STAT5 expression was evaluated in Tregs
using ﬂow cytometry.
Results: The results revealed that Treg percentage was signiﬁcantly
lower in the CVID patients than the control groups (healthy and
allergic individuals) (p<0.001). There was a signiﬁcant reduction in
Treg percentage in allergic patients compared to healthy subjects
(p<0.05). No signiﬁcant diﬀerence in Treg percentage between aller-
gic and non-allergic CVID patients was observed. The expression of p-
STAT5 in Tregs was signiﬁcantly lower in CVID patients than the
control groups (p<0.001). In addition, the expression of p-STAT5 in
Tregs of allergic patients was signiﬁcantly decreased compared to
healthy subjects (p<0.001). However, the deference of p-STAT5 level
was not statistically signiﬁcant between allergic and non-allergic
CVID patients.
Conclusion: These ﬁndings suggest that p-STAT5 signaling defect
and decreased Treg number may not participate in the development
of allergy in CVID patients.
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Introduction
Common variable immunodeﬁciency (CVID) is the most frequent symptomatic pri-
mary immunodeﬁciency characterized by impaired antibody responses, recurrent bac-
terial infections, and low levels of serum IgG, IgA, and/or IgM (Cunningham-Rundles
and Bodian, 1999; Egawa et al., 2018; Grace et al., 2009). Although the most important
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immunologic impairment is the lack of immunoglobulin production by B cells, in a
small proportion of CVID patients, defects in the number and function of T lympho-
cytes have been reported (Arumugakani et al., 2010; Sadeghi et al., 2015). The etiology
of CVID remains unknown, although mutations in ICOS, CD19, BAFF-R, and TACI
genes have been implicated (Fleischman et al., 1998). These patients usually suﬀer
from recurrent respiratory infections and have the elevated incidence of autoimmune,
lymphoproliferative granulomatous, and gastrointestinal diseases (Melo et al., 2009).
Moreover, allergic disorder is a major problem observed in some of patients with
CVID (Agondi et al., 2010; Özcan et al., 2014). Clinical studies have shown that CVID
patients are more susceptible to allergic disorders such as atopy and asthma than
healthy subjects (Agondi et al., 2010). In addition, it has been shown that there is a
bias from Th1 immunity towards Th2-type responses in CVID patients (Rezaei et al.,
2008a). In subjects with CVID, allergic immune responses are initiated by Th2 cell
activation and its cytokines production. In turn, cytokines induce the production of
allergen’s speciﬁc IgE, leading to liberation of active chemicals from diﬀerent immune
cells and subsequently symptoms of allergic diseases (Williams et al., 2012).
A key component in the maintenance of self-tolerance is regulatory T cells (Tregs)
(Arumugakani et al., 2010; Brusko et al., 2007). They constitute about 5–10% of the
peripheral blood CD4+ T cells and have an indispensable role in preventing the
development of autoimmune and allergic disorders (Genre et al., 2009; Grace et al.,
2009; Nava et al., 2009). Extensive data from the literature have reported that the
reduced number and impaired function of Tregs are largely associated with allergic
disorders and autoimmune diseases (Larche, 2007; Palomares et al., 2010). A great
number of studies have been carried out on the role of Tregs in preventing the
development of allergy in patients suﬀered from allergic disorders (Lesiak et al.,
2012; Wu et al., 2008). Immunomodulatory eﬀects of Tregs on the prevention of
allergic reactions are mediated by various mechanisms including: I) suppression of
Th2-type responses to allergen, II) inhibition of the activation of eosinophil, mast cell
and basophil and change of antibody isotype from IgE to IgG4, III) reduction of
dendritic cell function and immune cell migration to tissues (Larche, 2007; Özcan
et al., 2014).
Several lines of evidence show that signal transducer and activator of transcription
(STAT) protein 5 plays a fundamental role in survival, proliferation, and suppressive
functions of Tregs (Grace et al., 2009). STAT5 function is mediated by phosphoryla-
tion of this protein by kinases associated with transmembrane receptors (Grace et al.,
2009). The defects in the phosphorylation and function of STAT5 participate in the
reduced number and impaired function of Tregs which are associated with the risk of
developing autoimmune and allergic diseases (Nadeau et al., 2011).
Previous studies investigated the correlation between the reduction of Treg number
with chronic inﬂammation, splenomegaly, and autoimmune manifestations in CVID
patients (Arandi et al., 2013; Arumugakani et al., 2010; Horn et al., 2009; Nadeau
et al., 2011). This study is aimed to investigate and compare the percentage of Tregs
and their p-STAT5 expression level in CVID patients with allergic and without allergic
symptoms, allergic patients, and healthy subjects.
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Materials and methods
Subjects
A total of 36 individuals were recruited among those referred to the immunodeﬁciency
clinic of Alzahra hospital, Isfahan, Iran from September 2016 to March 2017 (Table 1).
CVID was diagnosed by specialist according to the European Society for immunodeﬁciency
(ESID) criteria including: a reduction in the serum antibody level of at least two isotypes of
IgG, IgM or IgA, Onset of immunodeﬁciency at greater than two years of age, absence of
isohemagglutinin, a poor response to vaccination, and the rejection of other causes of
hypogammaglobulinemia (Agata, et al.). Since all patients were treated with intravenous
immunoglobulin (IVIG), the sampling was performed after 3–4 weeks of IVIG injection
(before the next injection). None of CVID patients were on treatment with a drug known to
aﬀect the immune system and antibodies production (i.e. steroids, phenytoin, sulfasalazine,
antimalarial drugs, and gold salts) at the time of the blood draw and all of the patients are
currently alive. Allergy diagnostic were performed by specialist using clinical and laboratory
diagnostic criteria such as serum IgE measurement and skin prick test. A questionnaire was
used to the patients prospectively pertaining to their food allergies.
Antibody assay
To evaluate the immunologic situation of patients and aﬃrm CVID disease, the serum levels
of IgA and IgM in healthy volunteers, CVID, and allergic patients were measured using an
Enzyme-linked immunoasorbent assay (ELISA) kit according to the manufacturer’s protocol
(Mabtech, Sweden). The serum levels of IgA and IgM in healthy volunteers and allergic
patients were considered as control groups.
Isolation of peripheral blood mononuclear cells (PBMCs)
Heparinized blood samples (10 ml) were obtained from participants and PBMCs were isolated
using Ficoll density centrifugation based on the manufacturer’s instructions (Miltenyi Biotec,
Germany). Informed consent for participation in the study was obtained from contributors
before entering the study. The study and all protocols were approved by the Ethics Committee
of Isfahan University of Medical Sciences (reference number: 394637) and performed in
accordance with the declaration of Helsinki. After centrifugation, PBMCs were collected
from the interface between Ficoll and the plasma and washed twice with phosphate buﬀered
saline (PBS). PBMCs were suspended in PBS and cell viability was determined using trypan
blue dye exclusion. Cell count was also performed with a haemocytometer.
Table 1. Speciﬁcations of the subjects studied.
Patient groups (n = 16) Control groups (n = 20)
Allergic CVID
(n = 8)
Non-Allergic CVID
(n = 8)
Allergic patient group
(n = 10)
Healthy individual
(n = 10)
Sex (male/female) 5/3 4/4 5/5 6/4
Age (mean ± SD) 19.75 ± 4.26 22 ± 1.48 29.2 ± 5.28 22.4 ± 5.17
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Tregs staining
The isolated PBMCs (1 × 106 cell/ml) were stained by regulatory T cell staining kit
(eBioscience, USA). Accordingly, the cells were stained with ﬂuorescein isothiocyanate
(FITC) anti-human CD4 (eBioscience, USA) and Phycoerythrin (PE) anti-human CD25
antibodies (eBioscience, USA) or the matched isotype control IgG for 25 min at 4°C. The
matched isotype control antibodies were used as negative controls. After ﬁxation and
permeabilization with Fix/Perm buﬀer (eBioscience, USA), the cells were stained intra-
cellularly with Phycoerythrin/Cyanine5 (PE/cyn5) anti-human Foxp3 antibody
(eBioscience, USA) for 25 min at 4°C. Afterwards, the cells were washed three times
with PBS. Data were obtained using a FACSCalibur ﬂow cytometry (Becton Dickinson,
San Jose, CA) and analyzed by FlowJo software (v10.1, FlowJo, Ashland, OR, USA). The
CD4+, CD25+ and Foxp3+ cells were considered as Tregs.
Puriﬁcation of Tregs from peripheral blood
CD4+ CD25+ cells were isolated by a magnetic cell sorting (MACS) method using human
CD4+ CD25+ regulatory T cells isolation kit (Miltenyi Biotec, Germany). Following the
manufacturer’s protocol, two-step procedure was used to isolate Tregs. Brieﬂy, CD4+ T
cells were ﬁrst isolated from PBMCs using an indirect magnetic labeling of non CD4+ T
cells (negative selection) with biotin-conjugated monoclonal antibodies cocktail and anti-
biotin Micro Beads. Afterwards, a positive selection of CD25+ T cells was preformed
following a direct magnetic labeling of CD25+ T cells with anti-CD25 Micro Beads. To
determine the purity of CD4+CD25+ Foxp3+ Tregs, cells were stained with FITC anti-
human CD4 and PE anti-human CD25 antibodies or the matched isotype control IgG for
25 min at 4°C. The relevant isotype control antibodies served as negative controls. Fixation
and permebilization of the cells were carried out using Fix/perm buﬀer and then subjected
to intracellular staining using PE/cyn5 anti-human Foxp3 or the relevant isotype control
antibodies according to the manufacturer’s instructions (eBioscience, USA). All antibodies
and buﬀers were purchased from eBioscience (USA). The purity of cells was analyzed
using a FACSCalibur ﬂow cytometer. Cell samples with a > 92% purity were used in the
following experiments (data not shown).
Assessment of p-stat-5 expression level in Tregs
Tregs (5 × 105 cell/ml) were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium (Biosera, France) containing 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (Biosera, France) at 37°C and 5% CO2 for 4 hours. Afterwards, the cells were
stimulated with interleukin-2 (500 U/ml). After 15 min of incubation at 37°C, intracellular
(IC) ﬁxation buﬀer was used to ﬁx the cells in the dark for 45 min according to the
manufacturer’s protocol (eBioscience, USA). The ﬁxed cells were then permeabilized by
methanol for 45 min at 4°C based on the manufacturer’s instructions (eBioscience, USA).
Intracellular staining was performed with PE anti-human/mouse p-STAT5 antibody
(eBioscience, USA) for 45 min at 4°C and the stained cells were washed three times
with PBS. The percentage and mean ﬂuorescence intensity (MFI) of the stained cells were
measured using a FACSCalibur ﬂow cytometry and then analyzed using FlowJo software.
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Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM). The results were
analyzed using SPSS (V. 19, IBM, Chicago, IL.). Comparison between two groups with
normal and non-normal distribution was performed using Student’s t-test and Mann-
Whitney U test, respectively. p value < 0.05 was considered statistically signiﬁcant.
Result
Description of subjects
16 CVID subjects (aged 20.88 ± 8.8, mean ± standard deviation, range: 9 to 39 years) were
enrolled in the study. The onset of clinical symptoms in patients was varied and occurred
from an age of 2 years old to 20 (Table 2). The age in which the illness was diagnosed
varied from a range of 2 years old to 25 (data not shown). Eight patients had various
infections early from the birth as a consequence of consanguineous marriages. The most
common clinical manifestations among CVID patients were allergies, respiratory infec-
tion, and middle ear infection. Of the 16 CVID patients, eight had allergic symptoms,
while eight did not. Four CVID patients with allergic symptoms had frequent middle ear
infection, two had respiratory infection, lymphadenopathy, lymphohyperplasia, and joint’s
pain, and 1 had bronchiectasis, seizure, brain encephalitis, weight loss and hyperplasia
(Table 2). Of the eight non-allergic CVID patients, six had frequent middle ear infection,
three had bronchiectasis, two had respiratory infection, and 1 had lymphadenopathy,
chronic diarrhea, joint’s pain, nephritic syndrome, brain encephalitis, meningitis, pneu-
monia, and malignant history (Table 2). Table 2 depicted demographics and the clinical
characteristics of CVID subjects.
Immunologic properties of CVID patients
Since CVID disease is mainly associated with immunologic impairments in immunoglo-
bulin production by B cells, we evaluated the immunologic situation of patients in order to
Table 2. Demographics and clinical characteristics of CVID patients with allergic and without allergic
disorders.
Clinical characteristics Allergic CVID patients Non-allergic CVID patients
Frequent middle ear infection 4 6
Respiratory infection 2 2
Lymphadenopathy 2 1
Lymphohyperplasia 2 0
Joint’s pain 2 1
Bronchiectasis 1 3
Seizure 1 0
Brain encephalitis 1 0
Weight loss 1 0
Hyperplasia 1 0
Chronic diarrhea 0 1
Nephritic syndrome 0 1
Meningitis 0 1
Pneumonia 0 1
Malignant history 0 1
The onset age of clinical symptoms 2–20 2–10
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conﬁrm CVID disease. The levels of IgM and IgA antibodies in the serum of allergic and
non-allergic CVID patients were measured. A statistically signiﬁcant reduction in the
serum levels of IgA and IgM in allergic and CVID subjects with allergic and without
allergic symptoms was observed compared to healthy controls, as expected (p < 0.0001–
0.01, Figure 1A and B). However, no signiﬁcant diﬀerence was observed in the levels of
IgA and IgM between allergic and non-allergic CVID patients (Figure 1A and B).
Frequency of Tregs in healthy, CVID, allergic CVID, and allergic subjects
The percentage of Tregs in allergic, CVID patients, and healthy volunteers was deter-
mined. Our ﬂow cytometry results showed that the percentage of Tregs was signiﬁcantly
decreased in both allergic and non-allergic CVID patients compared to healthy individuals
and allergic patients (p < 0.01, Figure 2A and B). In addition, there was a signiﬁcant
diﬀerence in Treg percentage between allergic and healthy subjects (p < 0.05, Figure 2A
and B). However, no statistically signiﬁcant diﬀerence was observed in Treg percentage
between CVID patients with allergic and without allergic symptoms (Figure 2A and B).
Expression level of p-stat5 in tregs in CVID, allergic CVID, allergic, and healthy
subjects
Regarding known role of p-STAT5 in the development and survival of Tregs, the level of
p-STAT5 in Tregs was measured. Our results indicated that there was a signiﬁcant
decrease in the level of p-STAT5 expression in Tregs in both allergic and non-allergic
CVID patients compared to healthy subjects and allergic patients (p < 0.0001–0.001,
Figure 3A–C). This signiﬁcant reduction was also observed in allergic patients compared
to healthy individuals (p < 0.001–0.05, Figure 3A-C). Although a numerical reduction in
the average of p-STAT5 expression in allergic CVID patients was observed compared to
non-allergic CVID, but this decrease was not statistically signiﬁcant (Figure 3B and C).
Figure 1. The serum concentrations of IgA and IgM in CVID patients, and control groups. The levels of
IgA(A) and IgM (B) were measured by ELISA assay. The depicted results are representative of ten
independent experiments for control groups and eight independent experiments for CVID patients. All
data show mean ± SEM. **p < 0.01, ***p < 0.001,**** p < 0.0001.
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Figure 2. Percentage of Tregs in healthy volunteers, allergic, and CVID patients. PBMCs were isolated from
healthy subjects, allergic and CVID patients and then stainedwith anti-humanCD4, anti-humanCD25, and anti-
human Foxp3 antibodies. The percentage of Tregs was assessed using Flow cytometry (A) and then analyzed
(B). The depicted results are representative of 10 independent experiments for control groups and eight
independent experiments for patient groups. Data show mean ± SEM. *p < 0.05, **p < 0.01.
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Figure 3. p-STAT5 expression in Tregs from healthy volunteers, allergic, and CVID patients. Tregs were
isolated from PBMCs of healthy individuals, allergic, and CVID patients using an immunomagnetic
separation method. Fixation and permeabilization of the cells were preformed for intracellular staining
with PE anti-human p-STAT5 antibody. Data were acquired using Flow cytometry (A) and then analyzed
(B and C). Data are representative of ten independent experiments for control groups and eight
independent experiments for patient groups. Data are shown as mean ± SEM. *p < 0.05,
**p < 0.001, ***p < 0.0001.
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Discussion
CVID is a congenital disorder caused by inherent defects in the immune system that typically
present with hypogammaglobulinemia, impaired antibody responses and recurrent bacterial
infections (Arandi et al., 2013; Cunningham-Rundles and Bodian, 1999). CVID patients suﬀer
from non-infectious complications such as cancer, autoimmunity, and splenomegaly
(Aghamohammadi et al., 2006; Westh et al., 2017). Numerous studies have been conducted
to address the causes of these complications in CVID subjects (Aghamohammadi et al., 2006;
Azizi et al., 2016; Dadkhah et al., 2015). Some reports suggest that the reduction in the number
and defects in the function of Tregs play a critical role in the pathogenesis of non-infectious
complications in CVID patients (Arandi et al., 2013; Azizi et al., 2016). However, the possible
role of Tregs in causing allergies in CVID patients is not fully identiﬁed so far. In the current
study, we investigated whether the decreased number and impaired function of Tregs in CVID
patients participate in susceptibility to allergy.
A growing body of evidence indicates that there is an increased tendency in the
occurrence of allergic disorders in CVID patients (Agondi et al., 2010). Several mechan-
isms have been proposed to be responsible for developing allergy in CVID patients
including: 1) frequent respiratory infections and high antibiotics usage; previous studies
have shown that patients with hypogammaglobulinemia are more likely to have asthma
and allergies due to frequent infections and high antibiotics usage (Dadkhah et al., 2015).
Moreover, asthma can be concealed by repeated respiratory infections in CVID patients
(Agondi et al., 2010). 2) Defect in IgA secretion; in patients with CVID and selective IgA
deﬁciency, the reduced production of IgA causes mucosal immunodeﬁciency, which can
facilitate the development of allergic reactions, inﬂammation, and bronchial asthma
(Yazdani et al., 2016). 3) Th2 versus Th1 dominancy; several studies point to a bias of
Th1 immunity toward Th2 responses in patients with CVID (Rezaei et al., 2008a; Rezaei
et al., 2008b), although there are some papers that revealed a shift in immune responses
toward Th1 phenotype (Cunill et al., 2017; Unger et al., 2017). 4) Impaired function and
reduced number of Tregs; it has been reported that the defect in the function and
reduction in the frequency of Tregs play a fundamental role in the pathogenesis of allergic
disorders in CVID patients (Strickland and Holt, 2011). In this study, we unexpectedly
observed that there was no signiﬁcant diﬀerence in Treg percentage between allergic and
non-allergic CVID patients, however, the proportion of Tregs within CD4+ subpopulation
was signiﬁcantly lower in the CVID patients then the control groups, which is consistent
with other studies conducted on Tregs from patients with CVID (Bateman et al., 2012;
Grace et al., 2009; Horn et al., 2009; Melo et al., 2009; Paquin-Proulx et al., 2013). Several
lines of evidence demonstrated that the decreased number of Tregs participates in the
pathogenesis of autoimmune diseases in CVID patients (Agondi et al., 2010; Dadkhah
et al., 2015; Melo et al., 2009), while our data showed that the reduction in the number of
Tregs did not have signiﬁcant eﬀects the incidence of allergic disorders in CVID subjects.
Regarding that CVID disease is a heterogeneous disorder, it is likely that the development
and exacerbation of allergic reactions in patients may be mediated by other unknown
mechanisms and factors that some of them mentioned above. In line with this notion,
Scheﬀold et al. showed that the development of allergic disorders may result in some Th2
cells escape from Treg control (Bacher et al., 2016).
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Given that Tregs rely on p-STAT5 for their development, survival, and functions
(Grace et al., 2009; Melo et al., 2009), the critical question was whether the reduction of
Tregs in CVID patients was due to dysfunction of p-STAT5. The investigation of this
protein expression revealed that p-STAT5 level signiﬁcantly decreased in CVID patients
compared to control groups, although no signiﬁcant diﬀerence was observed in the level of
p-STAT5 between CVID patients with allergic and without allergic symptoms. In agree-
ment with these ﬁndings, Grace et al. indicated that the decreased level of p-STAT5 in
CVID patients was signiﬁcantly associated with the degree of T reg dysfunction (Grace
et al., 2009). Moreover, in a clinical study conducted on CVID patients with autoimmune
disease have demonstrated that p-STAT5b expression and Treg function was signiﬁcantly
decreased in patients with autoimmune diseases compared to patients without autoim-
mune diseases and healthy individuals (Nadeau et al., 2011). These results suggest that
impairment of intracellular signaling in Tregs from CVID patients contribute to the
reduction in the number of these cells. However, in contrast to other studies on CVID
patients with autoimmune diseases, the results of this study indicated that the defect in the
expression of p-STAT5 cannot aﬀect susceptibility to allergic disorders in CVID patients
through a reduction in the number of Tregs.
Taken together, the results of this study provide evidence to show that p-STAT5
signaling defect and decreased Treg number are not the main causes of allergy in CVID
patients. Regarding the fact that allergy is a hypersensitivity of the immune system to
innocuous environmental antigens, long-term use of antibiotics, environmental factors,
Th2 versus Th1 dominancy, and weakness in mucosal immunity of CVID patients may be
major causes that along with the reduced number and impaired function of Tregs make
them more susceptible to allergic reactions than healthy individuals. However, more
robust studies and studies with longitudinal design are required to clarify the role of
environmental factors and Tregs in the pathogenesis of allergic disorders in CVID
patients. Furthermore, it is noteworthy that the role of other molecules, which have a
pivotal role in the development and survival of Tregs such as GITR (glucocorticoid-
induced TNFR family related gene), Granzyme A, XCL1 (lymphotactin), and Foxp3 in
causing allergies in patients is investigated.
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